AIMT
Aimmune Therapeutics
AIMT
AIMT
Delisted
AIMT was delisted on the 12th of October, 2020.
155 hedge funds and large institutions have $1.48B invested in Aimmune Therapeutics in 2018 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 58 increasing their positions, 31 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
16% less call options, than puts
Call options by funds: $24.1M | Put options by funds: $28.6M
Holders
155
Holding in Top 10
7
Calls
$24.1M
Puts
$28.6M
Top Buyers
| 1 | +$64.3M | |
| 2 | +$63M | |
| 3 | +$23M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$22.8M |
| 5 |
DM
Deerfield Management
New York
|
+$22.6M |
Top Sellers
| 1 | -$23.9M | |
| 2 | -$18.9M | |
| 3 | -$17.5M | |
| 4 |
TG
TLP Group
Evanston,
Illinois
|
-$15M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$11.2M |